IoM Drug Safety Review Will Consider Advisory Committee Process, FDA Says
Executive Summary
The Institute of Medicine will consider FDA's use of advisory committees as part of its review of the agency's handling of drug safety issues
You may also be interested in...
National Academies Should Widen Definition Of Panelist Conflict, Report Says
Nearly 20% of panelists on National Academies of Science committees had financial ties to industry, a Center for Science in the Public Interest study found
National Academies Should Widen Definition Of Panelist Conflict, Report Says
Nearly 20% of panelists on National Academies of Science committees had financial ties to industry, a Center for Science in the Public Interest study found
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers